Nutriband (NASDAQ: NTRB) announced that it received a Notice of Allowance dated Nov. 3, 2026, from the United States Patent and Trademark Office (“USPTO”) for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The company intends to pursue full trademark registration in the United States and internationally and is preparing to submit its proposed global brand name to the U.S. Food and Drug Administration (“FDA”), European Medicines Agency (“EMA”) and other regulatory authorities for preapproval review. Nutriband said its naming process emphasizes minimizing potential medication errors associated with similar-looking or similar-sounding drug names.
The company’s lead product incorporates its proprietary AVERSA(TM) technology, designed to deter intentional abuse and misuse of fentanyl patches while reducing accidental exposure risks. Nutriband estimates potential peak annual U.S. sales of $80 million to $200 million for the product and is pursuing development for international markets. Its AVERSA technology uses aversive agents in transdermal patches to discourage misuse of medications with abuse potential, including opioids and stimulants, and is supported by patents issued in 46 countries.
To view the full press release, visit https://ibn.fm/FN3Or
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid…
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.…
Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended…
Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a…
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…
Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and…